Precision Biologics, Inc. announcesin vitroandin vivoefficacy of its novel tumor-specific ADC (PB-vcMMAE-5) against human carcinomas expressing truncated core 2 O-glycans. Recent data for several human cancer types expressing truncated core 2 O-glycans will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting onNovember 7th, 2025, National Harbor, MD, USA. […]

The Tribunal issued an Order in the above-named matter. A copy of the Order dated November 5, 2025 is available at capitalmarketstribunal.ca. Registrar, Governance & Tribunal SecretariatOntario Securities Commission Subscribe to notices and other alerts from the Capital Markets Tribunal:https://www.capitalmarketstribunal.ca/en/news/subscribe SOURCE Ontario Securities Commission https://rt.newswire.ca/rt.gif?NewsItemId=C7676&Transmission_Id=202511051607CANADANWWEB______C7676&DateId=20251105

DALLAS, Nov. 05, 2025 (GLOBE NEWSWIRE) — CMB Regional Centers (CMB), one of the most experienced regional center operators in the EB-5 industry, today announced the first I-526E approval for an investor in the CMB Group 88 – Hillwood Detroit Fairgrounds EB-5 project. Investors who secure approval of an I-526E petition by United States Citizenship

(NASDAQ:CPRX), Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE(R) Growth, Strong AGAMREE(R) Uptake and Growth, and Continued Demand for FYCOMPA(R) Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence

CMB Regional Centers Announces First I-526E Approval for Investor in Hillwood Detroit Fairgrounds Project GlobeNewswire November 05, 2025 DALLAS, Nov. 05, 2025 (GLOBE NEWSWIRE) — CMB Regional Centers (CMB), one of the most experienced regional center operators in the EB-5 industry, today announced the first I-526E approval for an investor in the CMB Group 88

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 05, 2025 Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE(R) Growth, Strong AGAMREE(R) Uptake and Growth, and Continued Demand for FYCOMPA(R) Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than

Lucid Group, Inc. (NASDAQ: LCID), maker of the world's most advanced electric vehicles, today announced key organizational changes designed to accelerate growth, streamline decision-making, and enhance accountability as the company scales globally. https://mma.prnewswire.com/media/1080273/LucidMotors_Logo.jpg To support these objectives, Lucid has made the following organizational changes: — Emad Dlala has been appointed Senior Vice President, Engineering and

— Revenue, Adjusted EBITDA1 and Adjusted Free Cash Flow1 once again all ahead of expectations — Adjusted EBITDA margin1 of 31.6%, highest in Company's history and 90 basis points increase over the prior year period2 — 7.3% organic price and volume growth with pricing accelerating sequentially by 50 basis points to6.3% — Fourth consecutive quarter

Financial Highlights — Produced 3,891 vehicles in Q3, up 116% compared to Q3 2024, with more than 1,000 additional vehicles built for Saudi Arabia for final assembly — Delivered 4,078 vehicles in Q3; up 47% compared to Q3 2024 — Q3 revenue of $336.6 million; up 68% compared to Q3 2024 — Subsequent to quarter

Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2025. https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg Key Highlights — On October 20, 2025, the Company announced accelerated transformation efforts, including: — Appointed Steve LaNeve as President and Chief Executive Officer. He succeeds Suzanne Winter, who will retire after six years of service and remain